Tyler Yagman


BIO:

Tyler Yagman is a resident of the firm’s New York office where he focuses on identifying and litigating shareholder derivative actions and complex federal securities class actions on behalf of individual and institutional shareholders.  He is also involved in cryptocurrency-based and other complex commercial matters.

Prior to joining the firm, Tyler focused on plaintiff-side antitrust, securities, and consumer protection litigation.  Tyler has a background in trading high-yield debt instruments and mortgage-backed securities.

Tyler is uniquely positioned as one of the few early blockchain technology trailblazers, founding a blockchain advising and mining group in 2012.  Tyler serves as the Co-Chair of the Blockchain Law Subcommittee and as a member of the Digital Law Task Force at the New York City Bar Association.

While in law school, Tyler was a research assistant at the Hofstra University Research Lab for Law, Logic & Technology, where he used artificial intelligence to help veterans navigate their benefit appeals process more efficiently.

Tyler has co-authored two commentary publications to the U.S. Securities and Exchange Commission (“SEC”) on proposed rule changes to the accredited investor definition and to investor protection mechanisms related to the facilitation of blockchain asset management at registered broker-dealers. His work was cited in a recent SEC rule that redefined the accredited investor definition and modernized investor protection standards.

  • Tyler Yagman & Nicholas Bruno, Comment Letter on Proposed Rule: Amending the “Accredited Investor” Definition (Mar.15, 2020)
  • SEC Accredited Investor, 17 C.F.R. §230.215 (2020) (citing to note 231 within the Final Rule)
  • Nicholas Bruno, et al., Comment Letter on Policy Statement: Custody of Digital Asset Securities by Special Purpose Broker-Dealers (Apr. 12, 2020)

REPRESENTATIVE CASES:

  • Martin v. Ford, No. 1:23-cv-04142 (N.D. Ill.) (Shareholder derivative suit against Abbott Laboratories, a major infant formula manufacturer, alleging that its board breached fiduciary duties by not implementing stronger oversight in its formula production.)
    • The suit centers on Abbott’s Sturgis, Mich., plant that was shut down in 2022 after the Food and Drug Administration found deadly bacteria in its powdered infant formula, Similac, and the company recalled the product. The recall led to a nationwide formula shortage.